R&D AstraZeneca cancer drugs approved in Japan AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months after scoring similar approvals in
News Groundbreaking lung cancer approval a big boost for AZ's Imf... AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.
News AstraZeneca spies an upturn at last in 2018 AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.
Views & Analysis Interview: AZ's immunotherapy gamble starts to pay off Robert Iannone, AstraZeneca's head of immune-oncology research, on the unpredictable immunotherapy market.
